Literature DB >> 30797863

Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.

Sharad Mangal1, Jiayang Huang1, Nivedita Shetty1, Heejun Park1, Yu-Wei Lin2, Heidi H Yu2, Dmitry Zemlyanov3, Tony Velkov4, Jian Li2, Qi Tony Zhou5.   

Abstract

Combinational antibiotic formulations have emerged as an important strategy to combat antibiotic resistance. The main objective of this study was to examine effects of individual components on the antimicrobial activity, physico-chemical properties, aerosolization and dissolution of powder aerosol formulations when three synergistic drugs were co-spray dried. A ternary dry powder formulation consisting of meropenem (75.5 %w/w), colistin (15.1 %w/w) and rifampicin (9.4 %w/w) at the selected ratio was produced by spray drying. The ternary formulation was characterized for in-vitro antibacterial activity, physico-chemical properties, surface composition, aerosol performance and dissolution. All of the formulations demonstrated excellent aerosolization behavior achieving a fine particle fraction of >70%, which was substantially higher than those for the Meropenem-SD and Colistin-Meropenem formulations. The results indicated that rifampicin controlled the surface morphology of the ternary and binary combination formulations resulting in the formation of highly corrugated particles. Advanced characterization of surface composition by XPS supported the hypothesis that rifampicin was enriched on the surface of the combination powder formulations. All spray-dried formulations were amorphous and absorbed substantial amount of water at the elevated humidity. Storage at the elevated humidity caused a substantial decline in aerosolization performance for the Meropenem-SD and Colistin-Meropenem, which was attributed to increased inter-particulate capillary forces or particle fusion. In contrast, the ternary combination and binary Meropenem-Rifampicin formulations showed no change in aerosol performance at the elevated storage humidity conditions; attributable to the enriched hydrophobicity of rifampicin on the particle surface that acted as a barrier against moisture condensation and particle fusion. Interestingly, in the ternary formulation rifampicin enrichment on the surface did not interfere with the dissolution of other two components (i.e. meropenem and colistin). Our study provides an insight on the impact of each component on the performance of co-spray dried combinational formulations.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosol performance; Dissolution; Dry powder inhaler; Solubility; Spray drying; Ternary combination

Mesh:

Substances:

Year:  2019        PMID: 30797863      PMCID: PMC6441383          DOI: 10.1016/j.ijpharm.2019.02.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  68 in total

Review 1.  Combination therapy as a tool to prevent emergence of bacterial resistance.

Authors:  J W Mouton
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Use of solid corrugated particles to enhance powder aerosol performance.

Authors:  N Y Chew; H K Chan
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

3.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  The influence of formulation components on the aerosolisation properties of spray-dried powders.

Authors:  Naumana R Rabbani; Peter C Seville
Journal:  J Control Release       Date:  2005-10-13       Impact factor: 9.776

Review 5.  Dry powder inhalers for pulmonary drug delivery.

Authors:  H W Frijlink; A H De Boer
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

Review 6.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

7.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

8.  Structural mechanism for rifampicin inhibition of bacterial rna polymerase.

Authors:  E A Campbell; N Korzheva; A Mustaev; K Murakami; S Nair; A Goldfarb; S A Darst
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

9.  The influence of relative humidity on the cohesion properties of micronized drugs used in inhalation therapy.

Authors:  Paul M Young; Robert Price; Michael J Tobyn; Mark Buttrum; Fiona Dey
Journal:  J Pharm Sci       Date:  2004-03       Impact factor: 3.534

10.  Lung infection--a public health priority.

Authors:  Joseph P Mizgerd
Journal:  PLoS Med       Date:  2006-01-17       Impact factor: 11.069

View more
  2 in total

1.  In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

Authors:  Jianting Chen; Maizbha U Ahmed; Chune Zhu; Shihui Yu; Weisan Pan; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

2.  Excipient-Free Inhalable Microparticles of Azithromycin Produced by Electrospray: A Novel Approach to Direct Pulmonary Delivery of Antibiotics.

Authors:  Beatriz Arauzo; Tania B Lopez-Mendez; Maria Pilar Lobera; Javier Calzada-Funes; Jose Luis Pedraz; Jesus Santamaria
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.